(NASDAQ: XGN) Exagen's forecast annual revenue growth rate of 9.55% is forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.12%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.92%.
Exagen's revenue in 2026 is $68,383,000.On average, 8 Wall Street analysts forecast XGN's revenue for 2026 to be $1,746,369,802, with the lowest XGN revenue forecast at $1,681,041,598, and the highest XGN revenue forecast at $1,826,483,828. On average, 9 Wall Street analysts forecast XGN's revenue for 2027 to be $1,936,701,014, with the lowest XGN revenue forecast at $1,846,778,093, and the highest XGN revenue forecast at $2,067,478,222.
In 2028, XGN is forecast to generate $2,198,569,509 in revenue, with the lowest revenue forecast at $2,085,912,180 and the highest revenue forecast at $2,336,377,230.